Researchers from Zhejiang Cancer Hospital and Peking University identified a stomach cancer biomarker intended to predict which patients are likely to benefit from neoadjuvant immunotherapy. The reported accuracy for the test in selecting responders supports a more tailored approach in gastric cancer, where treatment response variation often limits benefit from uniform immunotherapy strategies. The development is notable because it targets clinical decision-making ahead of and during treatment, aiming to align therapy choice with expected response. It also positions the biomarker as a potential tool for trial stratification in future studies. Next steps for the field will include independent validation, prospective evaluation, and an assessment of how the marker performs across subgroups defined by histology and baseline immune features.